Financhill
Sell
27

CANC Quote, Financials, Valuation and Earnings

Last price:
$24.50
Seasonality move :
0.75%
Day range:
$24.29 - $25.32
52-week range:
$24.00 - $30.11
Dividend yield:
2.98%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
134.5K
Avg. volume:
22.6K
1-year change:
-8.14%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CANC
Tema Oncology ETF
-- -- -- -- --
AGNG
Global X Aging Population ETF
-- -- -- -- --
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
-- -- -- -- --
MEDI
Harbor Health Care ETF
-- -- -- -- --
MEDX
Horizon Kinetics Medical ETF
-- -- -- -- --
MNTL
Tema Neuroscience and Mental Health ETF
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CANC
Tema Oncology ETF
$24.48 -- -- -- $0.96 2.98% --
AGNG
Global X Aging Population ETF
$30.10 -- -- -- $0.15 0.83% --
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
$28.99 -- -- -- $0.47 0.49% --
MEDI
Harbor Health Care ETF
$25.05 -- -- -- $0.13 0.54% --
MEDX
Horizon Kinetics Medical ETF
$26.23 -- -- -- $0.55 1.92% --
MNTL
Tema Neuroscience and Mental Health ETF
$24.67 -- -- -- $0.26 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CANC
Tema Oncology ETF
-- 1.218 -- --
AGNG
Global X Aging Population ETF
-- 1.018 -- --
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
-- 1.482 -- --
MEDI
Harbor Health Care ETF
-- 1.375 -- --
MEDX
Horizon Kinetics Medical ETF
-- 1.097 -- --
MNTL
Tema Neuroscience and Mental Health ETF
-- 0.000 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CANC
Tema Oncology ETF
-- -- -- -- -- --
AGNG
Global X Aging Population ETF
-- -- -- -- -- --
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
-- -- -- -- -- --
MEDI
Harbor Health Care ETF
-- -- -- -- -- --
MEDX
Horizon Kinetics Medical ETF
-- -- -- -- -- --
MNTL
Tema Neuroscience and Mental Health ETF
-- -- -- -- -- --

Tema Oncology ETF vs. Competitors

  • Which has Higher Returns CANC or AGNG?

    Global X Aging Population ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CANC
    Tema Oncology ETF
    -- -- --
    AGNG
    Global X Aging Population ETF
    -- -- --
  • What do Analysts Say About CANC or AGNG?

    Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Tema Oncology ETF is more attractive than Global X Aging Population ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CANC
    Tema Oncology ETF
    0 0 0
    AGNG
    Global X Aging Population ETF
    0 0 0
  • Is CANC or AGNG More Risky?

    Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.780, suggesting its less volatile than the S&P 500 by 21.991%.

  • Which is a Better Dividend Stock CANC or AGNG?

    Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.98%. Global X Aging Population ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.15 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CANC or AGNG?

    Tema Oncology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CANC
    Tema Oncology ETF
    -- -- -- --
    AGNG
    Global X Aging Population ETF
    -- -- -- --
  • Which has Higher Returns CANC or HRTS?

    Tema GLP-1, Obesity & Cardiometabolic ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CANC
    Tema Oncology ETF
    -- -- --
    HRTS
    Tema GLP-1, Obesity & Cardiometabolic ETF
    -- -- --
  • What do Analysts Say About CANC or HRTS?

    Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema GLP-1, Obesity & Cardiometabolic ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema GLP-1, Obesity & Cardiometabolic ETF, analysts believe Tema Oncology ETF is more attractive than Tema GLP-1, Obesity & Cardiometabolic ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CANC
    Tema Oncology ETF
    0 0 0
    HRTS
    Tema GLP-1, Obesity & Cardiometabolic ETF
    0 0 0
  • Is CANC or HRTS More Risky?

    Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CANC or HRTS?

    Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.98%. Tema GLP-1, Obesity & Cardiometabolic ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.47 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema GLP-1, Obesity & Cardiometabolic ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CANC or HRTS?

    Tema Oncology ETF quarterly revenues are --, which are smaller than Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema GLP-1, Obesity & Cardiometabolic ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema GLP-1, Obesity & Cardiometabolic ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema GLP-1, Obesity & Cardiometabolic ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CANC
    Tema Oncology ETF
    -- -- -- --
    HRTS
    Tema GLP-1, Obesity & Cardiometabolic ETF
    -- -- -- --
  • Which has Higher Returns CANC or MEDI?

    Harbor Health Care ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Harbor Health Care ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CANC
    Tema Oncology ETF
    -- -- --
    MEDI
    Harbor Health Care ETF
    -- -- --
  • What do Analysts Say About CANC or MEDI?

    Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Harbor Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Harbor Health Care ETF, analysts believe Tema Oncology ETF is more attractive than Harbor Health Care ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CANC
    Tema Oncology ETF
    0 0 0
    MEDI
    Harbor Health Care ETF
    0 0 0
  • Is CANC or MEDI More Risky?

    Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harbor Health Care ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CANC or MEDI?

    Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.98%. Harbor Health Care ETF offers a yield of 0.54% to investors and pays a quarterly dividend of $0.13 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Harbor Health Care ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CANC or MEDI?

    Tema Oncology ETF quarterly revenues are --, which are smaller than Harbor Health Care ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Harbor Health Care ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Harbor Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Harbor Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CANC
    Tema Oncology ETF
    -- -- -- --
    MEDI
    Harbor Health Care ETF
    -- -- -- --
  • Which has Higher Returns CANC or MEDX?

    Horizon Kinetics Medical ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Horizon Kinetics Medical ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CANC
    Tema Oncology ETF
    -- -- --
    MEDX
    Horizon Kinetics Medical ETF
    -- -- --
  • What do Analysts Say About CANC or MEDX?

    Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Horizon Kinetics Medical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Horizon Kinetics Medical ETF, analysts believe Tema Oncology ETF is more attractive than Horizon Kinetics Medical ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CANC
    Tema Oncology ETF
    0 0 0
    MEDX
    Horizon Kinetics Medical ETF
    0 0 0
  • Is CANC or MEDX More Risky?

    Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Horizon Kinetics Medical ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CANC or MEDX?

    Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.98%. Horizon Kinetics Medical ETF offers a yield of 1.92% to investors and pays a quarterly dividend of $0.55 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Horizon Kinetics Medical ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CANC or MEDX?

    Tema Oncology ETF quarterly revenues are --, which are smaller than Horizon Kinetics Medical ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Horizon Kinetics Medical ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Horizon Kinetics Medical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Horizon Kinetics Medical ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CANC
    Tema Oncology ETF
    -- -- -- --
    MEDX
    Horizon Kinetics Medical ETF
    -- -- -- --
  • Which has Higher Returns CANC or MNTL?

    Tema Neuroscience and Mental Health ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema Neuroscience and Mental Health ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CANC
    Tema Oncology ETF
    -- -- --
    MNTL
    Tema Neuroscience and Mental Health ETF
    -- -- --
  • What do Analysts Say About CANC or MNTL?

    Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Neuroscience and Mental Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema Neuroscience and Mental Health ETF, analysts believe Tema Oncology ETF is more attractive than Tema Neuroscience and Mental Health ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    CANC
    Tema Oncology ETF
    0 0 0
    MNTL
    Tema Neuroscience and Mental Health ETF
    0 0 0
  • Is CANC or MNTL More Risky?

    Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Neuroscience and Mental Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CANC or MNTL?

    Tema Oncology ETF has a quarterly dividend of $0.96 per share corresponding to a yield of 2.98%. Tema Neuroscience and Mental Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.26 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema Neuroscience and Mental Health ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CANC or MNTL?

    Tema Oncology ETF quarterly revenues are --, which are smaller than Tema Neuroscience and Mental Health ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema Neuroscience and Mental Health ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema Neuroscience and Mental Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema Neuroscience and Mental Health ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CANC
    Tema Oncology ETF
    -- -- -- --
    MNTL
    Tema Neuroscience and Mental Health ETF
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is American Tower Stock Undervalued?
Is American Tower Stock Undervalued?

The market action of late has been nothing short of…

Is Broadcom Stock Overvalued?
Is Broadcom Stock Overvalued?

The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock